GO
Loading...

Merck & Co Inc

More

  • KENILWORTH, N.J.— Merck& Co. says its board approved the repurchase of up to $10 billion more of its stock. The drugmaker said Tuesday that amount will be added to the $1.7 billion remaining available for repurchase under a prior authorization. Shares of the Kenilworth, New Jersey- based company rose 86 cents, or 1.5 percent, to $59.49 in aftermarket trading...

  • A trader works on the floor of the New York Stock Exchange.

    U.S. stocks closed lower as investors attempted to find clarity on the timing of a rate hike amid concerns of the dollar's impact on earnings.

  • March 24- Merck& Co Inc said on Tuesday that it would stop a large study of its Keytruda melanoma treatment early because an independent monitoring committee determined the drug succeeded in its goal of prolonging survival in previously untreated patients at advanced stage of the disease. The medicine, a PD-1 inhibitor that works by taking the brakes off the...

  • FRANKFURT, March 20- Germany's Merck KGaA will promote its deputy chief executive, Stefan Oschmann, to the top job next year to replace Karl-Ludwig Kley, Manager Magazin reported on Friday, citing company sources. Merck, which is also the world's largest maker of liquid crystals for flat-panel displays, is buying Sigma-Aldrich, putting it on track to become the...

  • Trader on the floor of the New York Stock Exchange.

    U.S. stocks closed mixed on Thursday as investors weighed the Federal Reserve statement that indicated a rate hike would come gradually.

  • FDA panel to discuss Ebola vaccine development in May Wednesday, 18 Mar 2015 | 8:16 AM ET

    March 18- The U.S. Food and Drug Administration said an advisory panel will discuss the development of Ebola vaccines, days after an American health worker was flown back after being tested positive for Ebola in Sierra Leone. Ebola has so far claimed about 10,000 lives in Sierra Leone, Liberia and Guinea. Other companies that are testing potential treatments for...

  • Cramer: These trends are wreaking havoc right now Tuesday, 17 Mar 2015 | 6:12 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Jim Cramer is seeing tons of inconsistency in the market right now. He no longer is trusting the trends that have made fortunes before.

  • March 17- Esperion Therapeutics Inc said its experimental drug lowered LDL or "bad" cholesterol levels in patients who were already on statins, the current standard of care. Needham& Co analyst Chad Messer said he expects the drug to be adopted faster as an additional therapy to statins rather than replacing statins altogether. There are about 35 million...

  • A hidden bear market in Dow threatens all stocks Tuesday, 17 Mar 2015 | 11:30 AM ET
    Pedestrians walk past IBM's building in New York.

    The Dow has a hidden bear market going on within it as a third of the members in the blue chip barometer have hit new 52-week lows this year.

  • March 17- Esperion Therapeutics Inc said its experimental drug showed greater reductions in cholesterol levels in patients on statins, compared with a placebo, in a mid-stage study. Many patients taking statins continue to have high LDL levels and are unable to tolerate its dosage, Chief Executive Tim Mayleben said. Esperion announced results from another...

  • Traders on the floor of the New York Stock Exchange.

    U.S. stocks closed lower, as a week of mixed economic data, dollar strength and low oil prices made traders cautious ahead of next week’s Fed meeting.

  • Why biotech investors may be hurting innovation Friday, 13 Mar 2015 | 3:27 PM ET

    Over the past five years, investor money is increasingly moving toward consumer software and later-stage life science ventures, a trend that could help develop new treatments.

  • CVS: Copycat drugs may bring price cuts of 40-50% Thursday, 12 Mar 2015 | 7:14 AM ET

    Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.

  • WASHINGTON, March 11- The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health Corp told Reuters. CVS is one of the largest U.S. pharmacy benefit managers and, along with rival Express Scripts, has put...

  • Fighting mosquitoes with more mosquitoes Wednesday, 4 Mar 2015 | 12:09 PM ET
    Mosquito Dengue Fever

    Constant vigilance is the method the Florida Keys has used to ward off mosquito-borne illnesses, but new methods may be on the horizon.

  • These 10 stocks could be due for a shake-up this year Wednesday, 4 Mar 2015 | 11:02 AM ET
    Exxon Mobil

    Data from eVestment show which stocks are poised to make a big run in 2015, based on the names institutional investors have already been trading.

  • LONDON, March 4- The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The idea of combining...

  • Europe closes lower; Barclays down 3% Tuesday, 3 Mar 2015 | 11:42 AM ET

    European equities closed lower on Tuesday as investors reacted to a slew of earnings news and economic data.

  • Your first trade for Monday, March 2 Friday, 27 Feb 2015 | 5:43 PM ET

    The "Fast Money" traders give their final trades of the day.

  • *Sales of 5 key drugs seen at close to 4 bln eur in 2015. LEVERKUSEN, Germany, Feb 26- Germany's largest drugmaker Bayer said it expects underlying core earnings to increase by more than 10 percent this year, banking on a boost from new drugs such as stroke prevention pill Xarelto. The company is benefiting from a strong dollar in particular as North America accounts...